Therapeutic activities of naringenin on efavirenz-induced sleep-like disorder in the midbrain of white albino mice

سال انتشار: 1399
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 233

فایل این مقاله در 9 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_IJBMS-23-11_013

تاریخ نمایه سازی: 19 دی 1399

چکیده مقاله:

Objective(s): Efavirenz, has proven to be effective in suppressing human immunodeficiency virus (HIV) viral load; however, complaints of sleep disorders including hallucination, and insomnia have greatly contributed to non-adherence to antiretroviral therapy. This study aimed at investigating therapeutic activities of naringenin on efavirenz-induced sleep disorder.Materials and Methods: Sixty mice were divided into six groups of control, combination antiretroviral therapy (cART), efavirenz, naringenin, naringenin/efavirenz and naringenin/cART. Efavirenz, cART, and naringenin were administered orally and daily at 15 mg/kg, 24 mg/kg and 50 mg/kg, respectively for 28 days. Post neurobehavioral test, oxidative stress, histology and immunohistochemistry for dopamine were carried out after administration process.Results: Efavirenz (p <0.0001) and cART (p <0.01) significantly increased immobility during open field (p <0.01), escape time in seconds (sec) in Morris water maze (p <0.001) and numbers of head-twitch response (HTR) (p <0.0001). Similarly, there was a significant increase in malondialdehyde (MDA) (p <0.0001) and decreased superoxide dismutase (SOD) (p <0.001) and reduced glutathione (GSH) (p <0.001); however, naringenin-treated groups potentiated anti-oxidant function by reducing oxidative stress (p <0.01). Histological evaluation demonstrated severe neurodegeneration, vacuolization and pyknosis in efavirenz and cART compared to naringenin groups. Dopaminergic neurons using immunohistochemial antibody (tyrosine hydroxylase) staining showed poor immunoreactivity in efavirenz and cART in contrast to naringenin groups.Conclusion: Efavirenz and cART have the potential of inducing sleep disorder possibly due to their capability to trigger inflammation and deplete dopamine level. However, naringenin has proven to be effective in ameliorating these damages.

نویسندگان

Olufunke Dosumu

Department of Anatomy, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria

Edidiong Akang

Department of Anatomy, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria

Oluwatomisin Faniyan

Department of Anatomy, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria

Alani Akanmu

Department of Haematology and Blood Transfusion, College of Medicine, University of Lagos, Idi-Araba, Lagos, Nigeria

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • 1. UNAIDS. Fact sheet: latest statistics on the status of ...
  • 2. Assefa Y, Gilks CF. Second-line antiretroviral therapy: so much ...
  • 3. Stubbs M. Update on antiretrovirals. South Afr J Anaesth ...
  • 4. WHO. Global health sector strategy on HIV/AIDS 2016-2021. 2018. ...
  • 5. Granich R, Gupta S, Wollmers M, Ruffner M, Williams ...
  • 6. Martínez-Salazar MF, Oaxaca-Navarro J, Leija-Salas A, García-Jiménez S, Sánchez-Alemán ...
  • 7. Oshinaike O, Akinbami A, Ojelabi O, Dada A, Dosunmu ...
  • 8. Mueller TE, Ellwanger JH, Michita RT, Matte MCC, Renner ...
  • 9. Apostolova N, Funes HA, Blas-Garcia A, Galindo MJ, Alvarez ...
  • 10. Gatch MB, Kozlenkov A, Huang RQ, Yang W, Nguyen ...
  • 11. Cavalcante GI, Chaves Filho AJM, Linhares MI, de Carvalho ...
  • 12. Adana MY, Akang E, Peter A, Jegede A, Naidu ...
  • 13. Corne S, Pickering R, Warner B. A method for ...
  • 14. Akang EN, Dosumu OO, Afolayan OO, Fagoroye AM, Osiagwu ...
  • 15. Dalwadi DA, Ozuna L, Harvey BH, Viljoen M, Schetz ...
  • 16. Akang EN, Adana MY, Peter AI, Naidu EC, Mackraj ...
  • 17. Akang E, Dosumu O, Afolayan S, Agumah R, Akanmu ...
  • 18. Oremosu AA, Akang EN, Dosumu OO, Usman IT, Akanmu ...
  • 19. Vorhees CV, Williams MT. Morris water maze: procedures for ...
  • 20. Kuo WY, Huang CH, Shih C, Jinn TL. Cellular ...
  • 21. Reiner K. Catalase test protocol. ASM MicrobeLibrary 2010; 11:1-9. ...
  • 22. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; ...
  • 23. Tsikas D. Assessment of lipid peroxidation by measuring malondialdehyde ...
  • 24. Fischer AH, Jacobson KA, Rose J, Zeller R. Hematoxylin ...
  • 25. Wang GQ, Zhang B, He XM, Li DD, Shi ...
  • 26. Cavalcante G, Capistrano V, Cavalcante F, Vasconcelos S, Macedo ...
  • 27. Ngaimisi E, Mugusi S, Minzi O, Sasi P, Riedel ...
  • 28. Waters L, Fisher M, Winston A, Higgs C, Hadley ...
  • 29. Gaida R, Truter I, Grobler C, Kotze T, Godman ...
  • 30. Gazzard B, Balkin A, Hill A. Analysis of neuropsychiatric ...
  • 31. Nelson M, Elion R, Cohen C, Mills A, Hodder ...
  • 32. Costa M, Abreu M, Rêgo N. Factors of nonadherence ...
  • 33. Habtewold A, Amogne W, Makonnen E, Yimer G, Nylen ...
  • 34. Jiang F, Desta Z, Shon JH, Yeo CW, Kim ...
  • 35. Yi LT, Li CF, Zhan X, Cui CC, Xiao ...
  • 36. Alzoubi KH, Malkawi BS, Khabour OF, El-Elimat T, Alali ...
  • 37. Havekes R, Bruinenberg VM, Tudor JC, Ferri SL, Baumann ...
  • 38. Tryon VL, Mizumori SJ. A novel role for the ...
  • 39. Cellini N. Memory consolidation in sleep disorders. Sleep Med ...
  • 40. Opii WO, Sultana R, Abdul HM, Ansari MA, Nath ...
  • 41. Gaida R, Truter I, Grobler C. Efavirenz: A review ...
  • 42. Manchope MF, Calixto-Campos C, Coelho-Silva L, Zarpelon AC, Pinho-Ribeiro ...
  • 43. Bulboaca AE, Bolboaca SS, Stanescu IC, Sfrangeu CA, Bulboaca ...
  • 44. Al-Dosari DI, Ahmed MM, Al-Rejaie SS, Alhomida AS, Ola ...
  • 45. Adjene JO, Avbunudiogba JA, Awhin PE, Igbigbi PS. Biochemical ...
  • 46. Shakeel S, Rehman MU, Tabassum N, Amin U. Effect ...
  • 47. Barres BA. The mystery and magic of glia: a ...
  • 48. Kang W, Balordi F, Su N, Chen L, Fishell ...
  • 49. de Sampaio e Spohr TCL, Stipursky J, Sasaki AC, ...
  • 50. de Pablo Y, Nilsson M, Pekna M, Pekny M. ...
  • 51. Schiweck J, Eickholt BJ, Murk K. Important shapeshifter: mechanisms ...
  • 52. Chamberlain SR, Grant JE. Behavioral Addictions. A Transdiagnostic Approach ...
  • 53. Claassen DO, Stark AJ, Spears CA, Petersen KJ, van ...
  • 54. Lim MM, Xu J, Holtzman DM, Mach RH. Sleep ...
  • 55. Mamelak M. Parkinson’s disease, the dopaminergic neuron and gammahydroxybutyrate. ...
  • 56. Zbarsky V, Datla KP, Parkar S, Rai DK, Aruoma ...
  • 57. Lou H, Jing X, Wei X, Shi H, Ren ...
  • نمایش کامل مراجع